Gastrin I (human): Precision CCK2 Receptor Agonist for Gastric Acid Secretion Research

Executive Summary: Gastrin I (human) is an endogenous peptide hormone that selectively activates CCK2 receptors on gastric parietal cells, inducing gastric acid secretion via proton pump stimulation (Saito et al., 2025). This peptide is a gold-standard research tool for in vitro studies of gastric acid secretion, receptor-mediated signaling, and gastrointestinal physiology (APExBIO B5358 product page). High-purity, lyophilized preparations, such as APExBIO’s offering, enable reproducible results and are essential for advanced organoid and cell-based models. Proper solubility and storage protocols are critical for experimental integrity. Gastrin I (human) is indispensable for studies targeting acid-related gastrointestinal disorders and pharmacological intervention development.

Biological Rationale

Gastrin I (human) is a 17-amino-acid peptide hormone with a molecular weight of 2098.22 Da, sequence structure C97H124N20O31S (APExBIO). It is endogenously produced in the G cells of the gastric antrum and released in response to food intake. Gastrin I binds specifically to cholecystokinin 2 (CCK2) receptors located on the basolateral membrane of gastric parietal cells (Saito et al., 2025). Engagement of CCK2 receptors initiates intracellular signaling cascades, principally via G-protein-coupled pathways, culminating in the activation of the H⁺/K⁺-ATPase (proton pump). This tightly regulated pathway is central to human gastric acid secretion and is a key focus in gastrointestinal physiology and pathophysiology research. Targeting this mechanism provides insight into acid-related disorders such as peptic ulcer disease and gastroesophageal reflux disease (GERD).

Mechanism of Action of Gastrin I (human)

Upon binding to the CCK2 receptor, Gastrin I (human) activates Gq/11 proteins, leading to phospholipase C (PLC) stimulation. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2), generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes Ca²⁺ from intracellular stores, while DAG activates protein kinase C (PKC). Increased intracellular Ca²⁺ and PKC activity drive the trafficking and activation of H⁺/K⁺-ATPase to the apical membrane, resulting in augmented gastric acid secretion (Saito et al., 2025). This sequence is specific: only CCK2 receptor-expressing cells respond robustly to Gastrin I, making the peptide a precise tool for dissecting receptor-mediated signaling in vitro. Gastrin I (human) does not appreciably activate CCK1 receptors, which distinguishes its pharmacological profile from other CCK/gastrin family peptides.

Evidence & Benchmarks

• Gastrin I (human) robustly stimulates gastric acid secretion in isolated parietal cell and organoid models, with dose-dependent effects measurable at nanomolar concentrations (Saito et al., 2025).
• Only CCK2 receptor–expressing cells respond to Gastrin I, confirming its selectivity and utility for receptor-mediated signal transduction studies (Saito et al., 2025).
• High-purity, lyophilized Gastrin I (human) (≥98% by HPLC/MS) is required for reproducible in vitro experiments and to avoid confounding off-target effects (APExBIO).
• In human pluripotent stem cell-derived intestinal organoid models, Gastrin I enables functional analysis of acid secretion and receptor-coupled pathways relevant for pharmacokinetics and disease modeling (Saito et al., 2025).
• Gastrin I (human) is insoluble in water and ethanol but dissolves at concentrations ≥21 mg/mL in DMSO, as required for in vitro assay preparation (APExBIO).

This article extends prior coverage such as Gastrin I (human): Advancing Proton Pump Activation in New Organoid Models, by providing quantitative benchmarks and clarifying solubility and storage parameters for translational researchers. In contrast to Mechanistic Precision and Strategic Horizons, this review focuses on technical reproducibility and model-specific considerations in gastric acid secretion assays.

Applications, Limits & Misconceptions

Gastrin I (human) is used extensively for:

• Dissecting CCK2 receptor signaling in parietal cells and gastrointestinal organoids.
• Modeling acid secretion in disease and drug testing contexts, including hiPSC-derived organoid platforms (Saito et al., 2025).
• Screening for acid secretion modulators and potential anti-ulcer therapeutics.
• Benchmarking proton pump activation and signal transduction components.

Limitations include:

• Requirement for precise solubilization (≥21 mg/mL in DMSO) and rapid use post-dilution, as aqueous solutions are unstable over time (APExBIO).
• Does not substitute for in vivo physiological complexity; use is limited to in vitro and ex vivo contexts.
• Cannot activate CCK1 receptors; not suitable for studies requiring broad-spectrum CCK receptor activation.
• Biological activity is dependent on CCK2 receptor expression level in the cell model.
• Not a direct marker for all forms of gastric pathophysiology—used as a mechanistic probe rather than a clinical diagnostic.

Common Pitfalls or Misconceptions

• Misconception: Gastrin I (human) is soluble in water for direct use.
  Correction: It is insoluble in water; DMSO is required for stock preparation.
• Pitfall: Long-term storage of reconstituted solutions.
  Correction: Only lyophilized peptide should be stored; solutions must be used promptly (APExBIO).
• Misconception: All gastrointestinal cells will respond to Gastrin I.
  Correction: Only CCK2 receptor–positive cells are responsive; other cell types may not exhibit effects.
• Pitfall: Using low-purity peptide in signaling assays.
  Correction: Purity ≥98% is necessary for reliable receptor-mediated response (APExBIO).
• Misconception: Gastrin I can be used for in vivo clinical diagnosis.
  Correction: The peptide is strictly a research tool for in vitro and ex vivo applications.

Workflow Integration & Parameters

For optimal results in gastric acid secretion pathway research and CCK2 receptor signaling studies, practitioners should:

• Reconstitute Gastrin I (human) at ≥21 mg/mL in DMSO; avoid aqueous solvents for stock solutions.
• Store lyophilized material desiccated at -20°C for maximal stability.
• Assess peptide purity by HPLC and mass spectrometry before use; APExBIO’s B5358 is validated to ≥98% purity (APExBIO).
• Use reconstituted solutions immediately; do not freeze-thaw working solutions.
• Confirm CCK2 receptor expression in model systems (e.g., parietal cells, hiPSC-derived intestinal organoids).
• Apply appropriate controls such as CCK2 receptor antagonists to verify specificity.

For advanced applications in human intestinal organoids, see Decoding CCK2 Signaling in Intestinal Organoids, which this article updates with new storage and solubility benchmarks for translational workflows.

Conclusion & Outlook

Gastrin I (human) remains the standard for selective CCK2 receptor activation and mechanistic studies of gastric acid secretion. The peptide is critical for interrogating proton pump activation, developing acid secretion pharmacology, and understanding gastrointestinal physiology. APExBIO’s B5358 (Gastrin I, human) product offers rigorously controlled purity and validated solubility, supporting high-fidelity in vitro research. As human organoid and stem cell–derived models mature (Saito et al., 2025), the precise deployment of Gastrin I will accelerate translational discoveries and the development of targeted therapies for acid-related gastrointestinal diseases. For further details and ordering, see the Gastrin I (human) product page.